Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant
HAMILTON, BERMUDA / ACCESSWIRE / March 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced positive
Stephen Kilmer Securities Exchange Commission Altamira Therapeutics Ltd Securities Exchange Altamira Therapeutics Median Tissue Culture Infectious Dose
Source: finanznachrichten.de